MeSH term
Frequency | Condition_Probility | Age of Onset | 2 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Body Mass Index | 3 | 0.0 |
Female | 122 | 0.0 |
Gene Frequency | 7 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Haplotypes | 3 | 0.0 |
Humans | 298 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Male | 126 | 0.0 |
Middle Aged | 89 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Reference Values | 10 | 0.0 |
Research Support, Non-U.S. Gov't | 151 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Vitamin D-Binding Protein/*genetics | 18 | 30.0 |
Oxidation-Reduction | 3 | 0.0 |
Peroxisomes/*enzymology | 2 | 22.0 |
Actins/*metabolism | 5 | 2.0 |
Amino Acid Sequence | 34 | 0.0 |
Animals | 105 | 0.0 |
Binding, Competitive | 13 | 0.0 |
Calcifediol/*metabolism | 4 | 50.0 |
Calcitriol/*metabolism | 4 | 13.0 |
Chromatography, Affinity | 2 | 0.0 |
Crystallography, X-Ray | 5 | 0.0 |
Molecular Sequence Data | 59 | 0.0 |
Molecular Weight | 11 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Protein Binding | 34 | 0.0 |
Protein Conformation | 7 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Rabbits | 16 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 100 | 0.0 |
Alleles | 12 | 0.0 |
Exons | 4 | 0.0 |
Introns | 4 | 0.0 |
*Polymorphism, Genetic | 9 | 0.0 |
Adult | 86 | 0.0 |
Genotype | 10 | 0.0 |
Japan | 4 | 0.0 |
Phenotype | 13 | 0.0 |
Blood Pressure | 15 | 2.0 |
Cohort Studies | 2 | 0.0 |
Cross-Sectional Studies | 9 | 0.0 |
Hypertension/epidemiology/*etiology | 2 | 33.0 |
Incidence | 3 | 0.0 |
Longitudinal Studies | 7 | 0.0 |
Risk Factors | 17 | 0.0 |
Smoking | 4 | 1.0 |
Systole | 8 | 9.0 |
*17-Hydroxysteroid Dehydrogenases | 2 | 66.0 |
Blotting, Western | 7 | 0.0 |
*Enoyl-CoA Hydratase | 2 | 50.0 |
Fibroblasts | 3 | 0.0 |
Aged | 55 | 0.0 |
*Circadian Rhythm | 10 | 4.0 |
Postmenopause/*blood | 3 | 6.0 |
Vitamin D-Binding Protein/*blood | 13 | 65.0 |
Blood Pressure/*physiology | 9 | 10.0 |
Binding Sites | 22 | 0.0 |
Ligands | 7 | 0.0 |
Models, Molecular | 5 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Structure-Activity Relationship | 10 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 14 | 0.0 |
Transfection | 18 | 0.0 |
Cell Line | 22 | 0.0 |
Chromatography, High Pressure Liquid | 7 | 0.0 |
Mice | 31 | 0.0 |
Mice, Knockout | 7 | 0.0 |
Cattle | 6 | 0.0 |
Cell Differentiation/drug effects | 6 | 0.0 |
HL-60 Cells | 3 | 0.0 |
Receptors, Calcitriol/chemistry/metabolism | 2 | 66.0 |
Stereoisomerism | 4 | 1.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 3 | 1.0 |
Blood Pressure/drug effects | 14 | 2.0 |
Calcium Channel Blockers/*therapeutic use | 3 | 10.0 |
Comparative Study | 49 | 0.0 |
Disease Progression | 2 | 0.0 |
Felodipine/*therapeutic use | 2 | 100.0 |
Prospective Studies | 10 | 0.0 |
DNA/metabolism | 5 | 0.0 |
DNA-Binding Proteins/*physiology | 5 | 0.0 |
Hela Cells | 15 | 0.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Nuclear Proteins/metabolism | 5 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
*Transcription, Genetic | 6 | 0.0 |
Age Factors | 10 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
English Abstract | 17 | 0.0 |
Hypertension/etiology/*genetics | 2 | 22.0 |
Antimutagenic Agents/*pharmacology | 2 | 13.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Aged, 80 and over | 12 | 0.0 |
Analysis of Variance | 4 | 0.0 |
*Blood Pressure | 21 | 17.0 |
Blood Pressure Monitoring, Ambulatory | 6 | 13.0 |
Time Factors | 17 | 0.0 |
Adolescent | 22 | 0.0 |
Anthropometry | 3 | 1.0 |
Cholesterol/blood | 5 | 0.0 |
Heart Rate/physiology | 3 | 3.0 |
Life Style | 3 | 2.0 |
Random Allocation | 6 | 1.0 |
Regression Analysis | 4 | 0.0 |
Triglycerides/blood | 2 | 0.0 |
Cell Division/drug effects | 9 | 0.0 |
Clinical Trials | 4 | 0.0 |
Parathyroid Hormone/blood | 6 | 3.0 |
Prevalence | 2 | 0.0 |
Radioimmunoassay | 6 | 0.0 |
Vitamin D-Binding Protein/blood | 20 | 95.0 |
Circadian Rhythm | 4 | 1.0 |
DNA-Binding Proteins/metabolism | 5 | 0.0 |
*Drosophila Proteins | 2 | 0.0 |
Gene Expression Regulation | 10 | 0.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
Rats | 40 | 0.0 |
Rats, Wistar | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
*Genome | 2 | 1.0 |
Receptors, Calcitriol/*metabolism | 2 | 2.0 |
Vitamin D/*metabolism | 6 | 20.0 |
*Antigens, Protozoan | 2 | 10.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
*Promoter Regions (Genetics) | 14 | 0.0 |
Protein Binding/genetics | 2 | 0.0 |
Blotting, Northern | 9 | 0.0 |
Cell Nucleus/metabolism | 6 | 0.0 |
Circadian Rhythm/physiology | 2 | 3.0 |
Dimerization | 3 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Kinetics | 18 | 0.0 |
Leucine Zippers | 10 | 6.0 |
Liver/metabolism | 9 | 1.0 |
Models, Biological | 2 | 0.0 |
Protein Biosynthesis | 4 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Proteins/*physiology | 2 | 1.0 |
Tissue Distribution | 6 | 0.0 |
Transcription, Genetic | 16 | 0.0 |
Calcitriol/*blood | 9 | 39.0 |
Immunodiffusion | 3 | 1.0 |
Nephrotic Syndrome/blood | 2 | 40.0 |
Pregnancy | 18 | 0.0 |
Radioligand Assay | 2 | 0.0 |
Serum Albumin/analysis | 3 | 1.0 |
*Chromosome Mapping | 2 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 3 | 1.0 |
European Continental Ancestry Group/*genetics | 4 | 1.0 |
3T3 Cells | 2 | 0.0 |
Binding Sites/genetics | 3 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Trans-Activation (Genetics) | 6 | 0.0 |
Transcription Factors/*genetics | 7 | 0.0 |
Tumor Cells, Cultured | 16 | 0.0 |
Circadian Rhythm/*physiology | 4 | 4.0 |
*DNA-Binding Proteins | 13 | 0.0 |
Molecular Conformation | 2 | 0.0 |
Hypertension/*drug therapy | 10 | 6.0 |
Leg | 2 | 4.0 |
Treatment Outcome | 5 | 0.0 |
Hypertension/*diagnosis/physiopathology | 2 | 100.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Trans-Activators/*genetics | 2 | 0.0 |
Virus Assembly | 2 | 7.0 |
Blood Pressure/*drug effects | 5 | 3.0 |
Double-Blind Method | 14 | 0.0 |
Body Weight/drug effects | 3 | 1.0 |
Organ Size/drug effects | 2 | 2.0 |
*Tetrahydroisoquinolines | 2 | 3.0 |
Calcium/metabolism | 2 | 0.0 |
Phosphorylation | 3 | 0.0 |
Vitamin D-Binding Protein/metabolism | 4 | 36.0 |
Actins/metabolism | 3 | 0.0 |
Base Sequence | 43 | 0.0 |
DNA Primers | 4 | 0.0 |
Deoxyribonuclease I/metabolism | 2 | 1.0 |
Mice, Mutant Strains | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Receptors, Calcitriol/metabolism | 5 | 9.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
Antihypertensive Agents/therapeutic use | 2 | 2.0 |
Diastole | 8 | 11.0 |
Pulse | 3 | 14.0 |
Brain/metabolism | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
Suprachiasmatic Nucleus/*metabolism | 2 | 50.0 |
Follow-Up Studies | 11 | 0.0 |
Electromyography | 3 | 1.0 |
Sleep/*physiology | 2 | 3.0 |
Molecular Structure | 4 | 0.0 |
Vitamin D-Binding Protein/*chemistry | 3 | 100.0 |
Osteocalcin/blood | 2 | 2.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 8 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Transcription Factors/*genetics/metabolism | 3 | 0.0 |
*Prenatal Exposure Delayed Effects | 2 | 4.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Amino Acids/chemistry | 2 | 1.0 |
DNA/chemistry | 2 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Deoxyribonucleases, Type II Site-Specific/chemistry | 2 | 40.0 |
Diabetes Mellitus, Type 1/*genetics | 2 | 0.0 |
Massachusetts | 2 | 11.0 |
Polymorphism, Genetic | 6 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Vitamin D-Binding Protein/chemistry/*genetics | 2 | 100.0 |
Cross-Over Studies | 6 | 0.0 |
Delayed-Action Preparations | 4 | 3.0 |
Drug Administration Schedule | 2 | 0.0 |
Ambulatory Care | 2 | 6.0 |
Antihypertensive Agents/*therapeutic use | 8 | 3.0 |
Multicenter Studies | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Risk | 5 | 0.0 |
*Aryl Hydrocarbon Hydroxylases | 2 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 2 | 5.0 |
Homozygote | 3 | 0.0 |
Mutation | 13 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Transcription Factors/genetics/*metabolism | 4 | 0.0 |
Bone Density | 2 | 1.0 |
*Adhesins, Bacterial | 2 | 11.0 |
*Bacterial Proteins | 2 | 1.0 |
Immunization | 2 | 0.0 |
Lyme Disease/*prevention & control | 2 | 100.0 |
United States | 2 | 0.0 |
*Vaccination | 2 | 3.0 |
Transcription Factors/*physiology | 4 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Solubility | 2 | 0.0 |
Administration, Oral | 5 | 0.0 |
Calcitriol/blood | 7 | 14.0 |
Albumins/*genetics | 2 | 18.0 |
Serum Albumin/genetics | 3 | 23.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
alpha-Fetoproteins/genetics | 3 | 14.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
*Exercise Test | 3 | 8.0 |
Potassium/blood | 2 | 2.0 |
Neurotransmitters/metabolism | 2 | 5.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Cloning, Molecular | 9 | 0.0 |
DNA Primers/genetics | 4 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Species Specificity | 8 | 0.0 |
Aging/*physiology | 2 | 0.0 |
*Muscle Contraction | 2 | 6.0 |
Vitamin D/*analogs & derivatives/blood | 2 | 22.0 |
*DNA Replication | 3 | 1.0 |
Blood Pressure Monitors | 2 | 25.0 |
*Heart Rate | 2 | 4.0 |
Carcinoma, Hepatocellular | 5 | 1.0 |
*Gene Expression Regulation | 4 | 0.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Liver/*metabolism | 7 | 1.0 |
Liver Neoplasms | 4 | 1.0 |
Organ Specificity/genetics | 2 | 1.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Carrier Proteins/*immunology | 2 | 4.0 |
Child | 11 | 0.0 |
Child, Preschool | 8 | 0.0 |
Infant | 7 | 0.0 |
Infant, Newborn | 10 | 0.0 |
Plasmodium vivax/*immunology | 2 | 28.0 |
Drug Therapy, Combination | 5 | 0.0 |
Hypertension/*drug therapy/physiopathology | 8 | 10.0 |
Echocardiography | 2 | 0.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
*Evolution, Molecular | 2 | 0.0 |
Genetics, Population | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Chronic Disease | 4 | 0.0 |
Cross Reactions | 3 | 0.0 |
DNA, Bacterial/genetics | 2 | 2.0 |
Affinity Labels/*chemical synthesis/metabolism | 2 | 100.0 |
CCAAT-Enhancer-Binding Proteins | 15 | 8.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Ultrafiltration | 2 | 3.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Cardiovascular Diseases/*etiology | 2 | 6.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Parenteral Nutrition/*methods | 2 | 100.0 |
Rats, Inbred Strains | 3 | 0.0 |
Heart Rate | 10 | 4.0 |
Calcium/blood | 11 | 5.0 |
Retrospective Studies | 2 | 0.0 |
CHO Cells | 4 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 3 | 0.0 |
Hamsters | 6 | 0.0 |
Nuclear Proteins/*physiology | 2 | 1.0 |
Hypertension/*physiopathology | 2 | 3.0 |
Nuclear Proteins/*metabolism | 4 | 0.0 |
Clonidine/*pharmacology | 3 | 13.0 |
Fatty Acids/metabolism | 2 | 1.0 |
Vitamin D-Binding Protein/chemistry/genetics/*metabolism | 3 | 100.0 |
Body Weight | 7 | 1.0 |
Evaluation Studies | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Staining and Labeling | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
*Multigene Family | 2 | 0.0 |
Adenovirus E2 Proteins/*genetics | 3 | 42.0 |
Adenoviruses, Human/*genetics | 6 | 3.0 |
*Gene Expression Regulation, Viral | 3 | 1.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Aging/metabolism | 3 | 1.0 |
Oligodeoxyribonucleotides | 6 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Transcription Factors/biosynthesis/*metabolism | 2 | 4.0 |
*Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Liver/*enzymology | 2 | 0.0 |
Plasmids | 7 | 0.0 |
Algorithms | 2 | 0.0 |
Cholesterol 7-alpha-Hydroxylase/*genetics | 2 | 10.0 |
*Leucine Zippers | 2 | 4.0 |
Organ Specificity | 4 | 0.0 |
RNA, Messenger/biosynthesis/metabolism | 2 | 4.0 |
DNA, Viral/genetics | 4 | 2.0 |
Blood Pressure Determination | 3 | 17.0 |
DNA-Binding Proteins/*metabolism | 11 | 0.0 |
Genes, Structural | 2 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Sequence Homology, Nucleic Acid | 7 | 0.0 |
*Estrogen Replacement Therapy | 2 | 1.0 |
Blood Pressure Determination/methods | 4 | 50.0 |
Vitamin D-Binding Protein/*analysis/metabolism | 2 | 100.0 |
Phosphates/blood | 3 | 5.0 |
Sterols/*metabolism | 2 | 6.0 |
Deoxyribonuclease I | 3 | 2.0 |
*Nuclear Proteins | 3 | 0.0 |
Restriction Mapping | 6 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Sex Factors | 4 | 0.0 |
Culture Media | 3 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/metabolism | 2 | 1.0 |
Insulin-Like Growth Factor Binding Protein 1/*genetics | 2 | 22.0 |
Transcription Factors/*metabolism | 6 | 0.0 |
Fetal Blood/*metabolism | 2 | 4.0 |
Antibodies, Monoclonal | 2 | 0.0 |
DNA, Single-Stranded | 2 | 2.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Chickens | 3 | 0.0 |
Calcifediol/*blood | 3 | 30.0 |
Guinea Pigs | 3 | 0.0 |
In Vitro | 4 | 0.0 |
Lipids/metabolism | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Blood Pressure/physiology | 4 | 2.0 |
Cold | 4 | 3.0 |
Exercise Test | 3 | 1.0 |
Osteocalcin/*blood | 2 | 9.0 |
Serum Albumin/metabolism | 6 | 3.0 |
Vitamin D-Binding Protein/*metabolism | 5 | 62.0 |
Cell Differentiation | 2 | 0.0 |
Liver Regeneration | 2 | 4.0 |
*Phosphoproteins | 2 | 1.0 |
Gene Deletion | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
DNA/genetics/*metabolism | 2 | 2.0 |
Cells, Cultured | 12 | 0.0 |
Glycerides/pharmacology | 2 | 33.0 |
Laurates/pharmacology | 2 | 100.0 |
Metallurgy | 2 | 15.0 |
Dogs | 2 | 0.0 |
Amino Acids/analysis | 4 | 1.0 |
Chromatography, Gel | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 11 | 0.0 |
Heat | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Rats/*genetics | 2 | 3.0 |
Heart Rate/*physiology | 2 | 6.0 |
Circadian Rhythm/*genetics | 2 | 9.0 |
DNA Mutational Analysis | 4 | 0.0 |
Isoelectric Focusing | 9 | 1.0 |
Adenoviruses, Human/*genetics/growth & development/metabolism | 2 | 100.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Biological Transport | 2 | 0.0 |
Skin/*metabolism/radiation effects | 2 | 66.0 |
Ultraviolet Rays | 4 | 0.0 |
Liver Neoplasms, Experimental | 2 | 4.0 |
Alkaline Phosphatase/blood | 2 | 1.0 |
Calcifediol/blood | 5 | 20.0 |
Phosphorus/blood | 4 | 11.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Trans-Activators | 2 | 4.0 |
Germany | 2 | 0.0 |
Hydroxycholecalciferols/blood | 6 | 54.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Liver/*physiology | 3 | 6.0 |
Adenoviruses, Human/*metabolism | 4 | 16.0 |
Blotting, Southern | 3 | 0.0 |
Autoradiography | 2 | 0.0 |
Hydrolysis | 2 | 0.0 |
Captopril/*therapeutic use | 2 | 5.0 |
Adenoviruses, Human/genetics/*metabolism | 2 | 13.0 |
Calcifediol/metabolism | 2 | 28.0 |
Kidney Failure, Chronic/metabolism/therapy | 2 | 15.0 |
DNA-Binding Proteins/*genetics | 9 | 0.0 |
Heart Rate/drug effects | 3 | 1.0 |
Adenovirus Early Proteins | 2 | 2.0 |
Haplorhini | 2 | 0.0 |
RNA, Viral/metabolism | 2 | 2.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Obesity/complications | 2 | 4.0 |
Parity | 3 | 2.0 |
Testosterone/blood | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Anorexia Nervosa/*blood | 2 | 11.0 |
Vitamin D/*blood | 8 | 50.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Genes | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Carrier Proteins/*metabolism | 3 | 0.0 |
Aging | 2 | 0.0 |
Immunoblotting | 3 | 0.0 |
Chymotrypsin/metabolism | 2 | 5.0 |
DNA Replication | 4 | 1.0 |
Osmolar Concentration | 2 | 0.0 |
Temperature | 4 | 0.0 |
Virus Replication | 4 | 0.0 |
Hela Cells/metabolism | 2 | 1.0 |
Adenoviruses, Human/*genetics/growth & development | 2 | 28.0 |
Adenovirus E2 Proteins | 2 | 66.0 |
Viral Proteins/*metabolism | 2 | 3.0 |
Gelsolin | 3 | 30.0 |
Immunosorbent Techniques | 2 | 0.0 |
*Breast Feeding | 2 | 3.0 |
*Genes, Viral | 4 | 2.0 |
Epidermis/*metabolism | 2 | 8.0 |
Serum Albumin/*metabolism | 2 | 4.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Immunoelectrophoresis | 2 | 0.0 |
Acetyltransferases/genetics | 2 | 5.0 |
Viral Proteins/*genetics | 2 | 2.0 |
*Genes, Structural | 3 | 0.0 |
24,25-Dihydroxyvitamin D 3 | 3 | 50.0 |
Enzyme Activation | 2 | 0.0 |
DNA Restriction Enzymes | 3 | 0.0 |
Hydroxycholecalciferols/*blood | 4 | 50.0 |
Dihydroxycholecalciferols/blood | 2 | 50.0 |
*Pregnancy | 2 | 1.0 |
25-Hydroxyvitamin D 2 | 2 | 50.0 |
Epidemiologic Methods | 2 | 3.0 |
Genes, Viral | 2 | 0.0 |
Genetic Engineering | 3 | 3.0 |
Carrier Proteins/*blood | 6 | 2.0 |
Body Height | 2 | 1.0 |
Growth Hormone/blood | 2 | 0.0 |
Hydrocortisone/blood | 2 | 0.0 |
Norepinephrine/blood | 2 | 1.0 |
Prolactin/blood | 2 | 0.0 |
Syndrome | 2 | 0.0 |
*Aging | 2 | 1.0 |
Calcitonin/blood | 2 | 6.0 |
Viral Proteins/genetics | 2 | 3.0 |
Vitamin D-Binding Protein | 8 | 28.0 |
Carrier Proteins/blood | 2 | 1.0 |
Immune Sera | 2 | 0.0 |
Skin/metabolism | 2 | 1.0 |
Fetal Blood/analysis | 2 | 3.0 |
Electrophoresis, Disc | 2 | 8.0 |
DNA Helicases/*analysis | 2 | 66.0 |
Densitometry | 2 | 1.0 |
Skin/*analysis | 2 | 18.0 |
Psoriasis/*metabolism | 3 | 12.0 |
Chromatography, DEAE-Cellulose | 2 | 3.0 |
